Japanese pharma company Eisai has granted exclusive development and marketing rights for lorcaserin hydrochloride, its anti-obesity agent, to Brazil’s Eurofarma Laboratórios.
Lorcasrin, a generic of Belviq, will now be rolled out in 17 counties in Latin American and the Caribbean – excluding Brazil.
Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country.
Lorcaserin is a novel chemical entity that is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain.
It was approved in the US in 2012 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients and launched in the US in June 2013.
Lorcaserin was approved in Mexico and Brazil with the same indication as for the United States in July 2016 and December 2016, respectively.
With this latest step, Eisai said it aims to make lorcaserin widely available to appropriate patients as soon as possible.